论文部分内容阅读
本文旨在评价FедеонРихтер公司生产的кавинтон治疗美尼尔氏病患者之疗效和前景。作者们选择了20名(女14,男6;年龄35～60岁)美尼尔氏病患者进行治疗观察。17名患者每月发作数次,3名1～2月发作一次,病程3～20年。全部患者均经电测听、前庭功能和脑血流图检查,后者显示损害位于椎-基底动脉系统者有17名,其中8名在颈内动脉。患者均曾由神经科、眼科医生会诊,并行内耳道与颈椎X线照相,排除了中枢神经系统器质性病变。[治疗]кавинтон20mg溶于5～20ml生理盐水静脉注射(10日);然后肌肉注射кавинтон10mg,每日二次(20日);继口服本药每次一片(5mg),一日三次,计10～20天。治疗期间,眩晕迅速减轻。
This article aims to evaluate the efficacy and prospects of the кавинтон company of Fедеон Рихтер in the treatment of Meniere’s disease. The authors selected 20 patients (14 men, 6 men and 35-60 years old) with Meniere’s disease for treatment. 17 patients attack several times per month, 3 1 to 2 months attack, the course of 3 to 20 years. All patients underwent electrical audiometry, vestibular function and cerebral blood flow tests, which showed that 17 of the patients with lesions in the vertebrobasilar artery system, of which 8 were in the internal carotid artery. Patients were neurological, ophthalmologist consultation, parallel internal auditory canal and cervical radiography, ruled out the central nervous system organic disease. [Treatment] кавинтон20mg dissolved in 5 ~ 20ml saline intravenously (10 days); then intramuscular injection кавинтон10mg, twice daily (20 days); following oral administration of the drug each time (5mg), three times a day, 20 days. During treatment, dizziness quickly reduced.